Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy | Zendy

Michael B. Atkins | Zendy; Cristina Julián | Zendy; Matthew H. Secrest | Zendy; Janet Lee | Zendy; Ana M Abajo-Guijarro | Zendy; Edward McKenna | Zendy

Open Access

Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy

Author(s) -

Michael B. Atkins,

Cristina Julián,

Matthew H. Secrest,

Janet Lee,

Ana M Abajo-Guijarro,

Edward McKenna

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-1536

Subject(s) - medicine , melanoma , hazard ratio , oncology , immunotherapy , ipilimumab , targeted therapy , immune checkpoint , cancer research , cancer , confidence interval

Aim: To assess overall survival (OS) in patients with advanced BRAF-mutant melanoma by first-line (1L) targeted therapy (TT) or checkpoint inhibitor (CPI) use, second-line (2L) TT or CPI use, and treatment sequence. Patients & methods: Advanced BRAF-mutant melanoma patients treated with 1L CPI or TT were selected from a real-world, electronic health record-derived database. Results: CPI was associated with improved survival after adjustment for potential confounders (hazard ratio, 0.75 [95% CI, 0.66–0.87]). Median OS was similar between 2L therapies and among likely treatment sequences. Conclusion: This real-world study demonstrated a survival benefit with 1L CPI versus TT. Analyses of 2L and treatment sequences were unable to detect or rule out clinically relevant differences in OS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research